Natural Alternatives Q1 net loss narrows

Natural Alternatives International

12/11/2025 21:53

Overview

NAI fiscal Q1 2026 net loss narrows to $0.3 mln from $2.0 mln last year

Company's Q1 net sales rise 13.8% to $37.7 mln, driven by private-label sales

CarnoSyn® beta-alanine revenue declines 33.9% due to decreased raw material orders

Outlook

Company anticipates net loss in first half, net income in second half of fiscal 2026

NAI focuses on expanding client relationships and TriBsyn™ adoption

Company addressing supply chain disruptions for anticipated sales growth

Result Drivers

PRIVATE-LABEL SALES - Increased orders from existing and new customers drove a 17.7% rise in private-label contract manufacturing sales

GROSS PROFIT IMPROVEMENT - Improved factory utilization and lower volume rebates contributed to higher gross profit

CARNOSYN® REVENUE DECLINE - Decreased raw material orders led to a 33.9% drop in CarnoSyn® beta-alanine revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
$37.73 mln
Q1 Net Income
-$291,000
Q1 Gross Profit
$4.40 mln
Q1 Operating Income
$284,000
Q1 Pretax Profit
-$199,000


Press Release: ID:nGNX6j45MJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)